📇 Rhumatologue · VALENCIENNES CEDEX · (59) · Salarié
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Praticien-chercheur
6 articles scientifiques publiés — formation continue solide
Délais de RDV courts dans la région
126.7 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
CH VALENCIENNES
114 AV DESANDROUINS BP 479, 59322 VALENCIENNES CEDEX
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Infectious diseases and therapy · 2014
BMC infectious diseases · 2023
Abstract Background The intravenous form of fosfomycin, a bactericide antibiotic used to treat multiresistant bacterial infections is little prescribed. The most common reported adverse effects are hypokaliemia and hypernatremia. We describe a case of agranulocytosis, a rarely described side effect that may be fatal. Case presentation A 45 year-old woman was admitted to the intensive care unit for post-surgical meningitis following meningioma resection. Meropenem and vancomycin were first introduced. A DRESS-syndrom with meropenem was suspected. Neutropenia was diagnosed three days after the introduction of parenteral fosfomycin and agranulocytosis four days later. Eosinophilia was also observed. A bone marrow aspiration was performed showing a disappearance of the neutrophil granulocyte line and a significant eosinophilia. Meropenem was discontinued. Fosfomycin was maintained and filgrastim was added. As filgrastim had no effect, the relationship with fosfomycin was suspected, so it was then withheld. An increase of the neutrophil count was observed. Because of the complexity of the case, the unfavorable course of the illness and the urgent need for revision surgery, a rechallenge with fosfomycin was done followed by a decrease of the neutrophil count. Conclusion This is the third paper reporting agranulocytosis induced by fosfomycin, and the first detailed description of a case. Based on chronological and semiological criteria and bibliographic data, the event was qualified as probable with the Naranjo adverse drug probability scale. Literature data is scarce. The summary of product characteristics mentions that only a few cases of transient neutropenia and agranulocytosis have been reported. An analysis of the FDA Adverse Event Reporting System Database highlighted a higher than expected frequency of agranulocytosis in patients treated with fosfomycin. Parenteral fosfomycin is often used in patients receiving other medications, so that it is rarely the only suspect. In our case, the results of the bone marrow aspiration, the sudden drop of the neutrophil count with concomitant eosinophilia and the absence of improvement despite the dose decrease, point towards an immuno-allergic mechanism. However, the overlap between the suspected DRESS induced by meropenem and the agranulocytosis do not allow to conclude with certainty on the causality. Awareness should be raised about this side effect.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Journal of fungi (Basel, Switzerland) · 2025 · Case Reports
Nadji S, Ettahar N, Leroy J, Dewulf G, et al.
Annals of clinical microbiology and antimicrobials · 2024 · Case Reports
Benhalima I, Jacquemont L, Milière L, Tone A, et al.
BMC infectious diseases · 2023 · Review
Matusik E, Demanet J, Alves I, Tone A, et al.
Journal of fungi (Basel, Switzerland) · 2025 · Case Reports
Nadji S, Ettahar N, Leroy J, Dewulf G, et al.
Annals of clinical microbiology and antimicrobials · 2024 · Case Reports
Benhalima I, Jacquemont L, Milière L, Tone A, et al.
BMC infectious diseases · 2023 · Review
Matusik E, Demanet J, Alves I, Tone A, et al.
Infectious diseases and therapy · 2014 · Journal Article
Legout L, D'Elia P, Sarraz-Bournet B, Ettahar N, et al.
Lancet (London, England) · 2013 · Case Reports
Guery B, Poissy J, el Mansouf L, Séjourné C, et al.
Diagnostics (Basel, Switzerland) · 2025 · Journal Article
Thiboud PE, François Q, Faure C, Chaufferin G, et al.